Maʻemaʻe Kiʻekiʻe 540737-29-9 Tofacitinib citrate no ka JAK Pathway Inhibitor
Huahanainoa | Tofacitinib Citrate |
Nā huaʻōlelo like | (3R,4R)-1-(Cyanoacetyl)-4-methyl-N-methyl-N-1H-pyrrolo[2,3-d]pyrimidin-4-yl-3-piperidinamine 2-hydroxy-1,2,3 -propanetricarboxylate;CP 690500-10;CP 690550-10;(3R,4R)-4-Methyl-3-(methyl-7H-pyrrolo[2,3-d]pyrimidin-4-ylamino)-beta-oxo-1-piperidinepropanenitrile 2-Hydroxy-1,2,3-propanetricarboxylate |
CAS No. | 540737-29-9 |
Ka nana aku | ʻO ke keʻokeʻo i ka pauka keʻokeʻo |
ʻĀpana Molekala | C16H20N6OC6H8O7 |
Kaumaha Molekala | 504.50 |
Palapala noi | Papa lāʻau lapaʻau a i ʻole kumu noiʻi |
Hoʻopili | E like me kāu noi |
Waihona | E mālama i loko o nā pahu paʻa a me ka māmā ma kahi anuanu |
Tofacitinib Citrate (CAS #540737-29-9) | ||
NA MEA | NA KUMU | HANA |
Ka nana aku | ʻO ke keʻokeʻo i ka pauka keʻokeʻo | Pauda keʻokeʻo |
ʻIkepili | HPLC;IR;HNMR | Hoʻokō |
Ka hoʻoheheʻe | Hiki ke hoʻoheheʻe ʻia i DMSO ma 100mg/ml, hiki ʻole ke hoʻoheheʻe ʻia i ka ethanol, hiki ke hoʻoheheʻe ʻia i ka wai etc. | Hoʻokō |
Nalo ma ka maloo | ≤0.5% | 0.12% |
Ke koena ma ka ʻā | ≤0.1% | 0.05% |
Nā metala kaumaha | ≤10ppm | Hoʻokō |
Na mea pili | Diastereomer (RS+SR) ≤0.1% Hoʻokahi haumia ≤0.15% Huina haumia ≤1.0% | 0.05% 0.14% 0.18% |
Enantiomorphism Isomers | ≤0.2% | Hoʻokō |
Nā mea hoʻoheheʻe koena | Ethanol ≤5000ppm Methanol ≤3000ppm Toluene ≤890ppm | Hoʻokō |
Maʻiʻo Citrate | 36.2%~40% | 37.8% |
Maemae | ≥99.0% | 99.38% |
Hoʻāʻo | 60.68%~63.16% o Tofacitinib INN 98% ~ 102% o Tofacitinib Citrate INN | 62.04%
99.12% |
Manaʻo: Hoʻokō |
ʻIkepili Hui
√ Ka ʻike piha o ka papa hoʻokele ma ka hale hana a me nā mea ʻenehana akamai; √ ʻO ka maikaʻi ka mea i manaʻo nui ʻia, ʻōnaehana QC koʻikoʻi; √ 11 makahiki i ʻike i ka lawe ʻana i nā hui kūʻai; √ Keʻena hana R&D kūʻokoʻa; √ ʻElua mau papa hana GMP lōʻihi i pūlima ʻia; √ Nā waiwai waiwai o nā hale hana palaualelo no ka papahana maʻamau; √ Kiʻekiʻe Efficiency hui hana me ke ala mau.E kākau i kāu leka ma aneʻi a hoʻouna mai iā mākou